Literature DB >> 31705979

A drug-likeness toolbox facilitates ADMET study in drug discovery.

Chen-Yang Jia1, Jing-Yi Li1, Ge-Fei Hao2, Guang-Fu Yang3.   

Abstract

Undesirable pharmacokinetic (PK) properties or unacceptable toxicity are the main causes of the failure of drug candidates at the clinical trial stage. Since the concept of drug-likeness was first proposed, it has become an important consideration in the selection of compounds with desirable bioavailability during the early phases of drug discovery. Over the past decade, online resources have effectively facilitated drug-likeness studies in an economical and time-efficient manner. Here, we provide a comprehensive summary and comparison of current accessible online resources, in terms of their key features, application fields, and performance for in silico drug-likeness studies. We hope that the assembled toolbox will provide useful guidance to facilitate future in silico drug-likeness research.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31705979     DOI: 10.1016/j.drudis.2019.10.014

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  19 in total

1.  In Silico Tools and Software to Predict ADMET of New Drug Candidates.

Authors:  Supratik Kar; Kunal Roy; Jerzy Leszczynski
Journal:  Methods Mol Biol       Date:  2022

2.  Network analysis for elucidating the mechanisms of Shenfu injection in preventing and treating COVID-19 combined with heart failure.

Authors:  Wei Zhou; Ziyi Chen; Zhangfu Fang; Damo Xu
Journal:  Comput Biol Med       Date:  2022-07-14       Impact factor: 6.698

3.  Investigation on the Mechanism of Qubi Formula in Treating Psoriasis Based on Network Pharmacology.

Authors:  Lin Zhou; Lingyun Zhang; Disheng Tao
Journal:  Evid Based Complement Alternat Med       Date:  2020-06-21       Impact factor: 2.629

4.  Combined use of the hepatitis C drugs and amentoflavone could interfere with binding of the spike glycoprotein of SARS-CoV-2 to ACE2: the results of a molecular simulation study.

Authors:  Kateryna V Miroshnychenko; Anna V Shestopalova
Journal:  J Biomol Struct Dyn       Date:  2021-04-26

5.  Drug-likeness scoring based on unsupervised learning.

Authors:  Kyunghoon Lee; Jinho Jang; Seonghwan Seo; Jaechang Lim; Woo Youn Kim
Journal:  Chem Sci       Date:  2021-12-14       Impact factor: 9.825

6.  Synthesis and preliminary structure-activity relationship study of 3-methylquinazolinone derivatives as EGFR inhibitors with enhanced antiproliferative activities against tumour cells.

Authors:  Yan Zhang; Qin Wang; Luolan Li; Yi Le; Li Liu; Jing Yang; Yongliang Li; Guochen Bao; Longjia Yan
Journal:  J Enzyme Inhib Med Chem       Date:  2021-12       Impact factor: 5.051

Review 7.  Anticancer Plants: A Review of the Active Phytochemicals, Applications in Animal Models, and Regulatory Aspects.

Authors:  Tariq Khan; Muhammad Ali; Ajmal Khan; Parveen Nisar; Sohail Ahmad Jan; Shakeeb Afridi; Zabta Khan Shinwari
Journal:  Biomolecules       Date:  2019-12-27

Review 8.  Cheminformatics to Characterize Pharmacologically Active Natural Products.

Authors:  José L Medina-Franco; Fernanda I Saldívar-González
Journal:  Biomolecules       Date:  2020-11-17

9.  Determination of Novel Anti-Cancer Agents by Targeting OGG1 Enzyme Using Integrated Bioinformatics Methods.

Authors:  Ziyad Tariq Muhseen; Mustafa Hussein Ali; Nawar Rushdi Jaber; Dheyaa Shakir Mashrea; Ali Mamoon Alfalki; Guanglin Li
Journal:  Int J Environ Res Public Health       Date:  2021-12-16       Impact factor: 3.390

10.  An Investigation of the Antigastric Cancer Effect in Tumor Microenvironment of Radix Rhei Et Rhizome: A Network Pharmacology Study.

Authors:  Xinmiao Wang; Guanghui Zhu; Haoyu Yang; Ruike Gao; Zhe Wu; Ying Zhang; Xiaoyu Zhu; Xiaoxiao Zhang; Jie Li
Journal:  Evid Based Complement Alternat Med       Date:  2021-06-24       Impact factor: 2.629

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.